2025-01-30 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Summary and Comparison to S&P 500 (VOO):**

Johnson & Johnson is a multinational corporation that manufactures medical devices, pharmaceuticals, and consumer packaged goods.  The provided data shows JNJ's cumulative return at 29.01% significantly lags behind the S&P 500's cumulative return of 119.94%.  The difference is -90.9%, placing it at the 6.9th percentile of its historical relative performance against the S&P 500. This indicates JNJ's underperformance compared to the broader market. The provided CAGR data shows inconsistent performance over the years, with periods of strong growth followed by periods of decline or stagnation.  The negative alpha consistently indicates underperformance relative to the market benchmark.

**2. Recent Price Movement:**

* **Closing Price:** $151.15
* **5-Day Moving Average:** $149.58
* **20-Day Moving Average:** $146.03
* **60-Day Moving Average:** $149.40

The price is slightly above the 5-day and 60-day moving averages, suggesting a recent minor upward trend.  The price is significantly higher than the 20-day moving average, indicating a more substantial upward movement in the recent period.  The positive change from the previous close (+$0.51) suggests a minor upward momentum.

**3. Technical Indicators and Expected Return:**

* **RSI:** 59.64 (Neutral; neither overbought nor oversold)
* **PPO:** 0.65 (Positive; suggesting upward momentum)
* **20-Day Relative Divergence Change:** +5.7% (Short-term upward trend)
* **Expected Return (2+ years):** -381.0% (Significant projected underperformance relative to the S&P 500 over the long term)

The technical indicators present a mixed picture. While the PPO suggests upward momentum and the recent relative divergence shows short-term strength, the RSI is neutral and the extremely negative expected return raises serious concerns about long-term investment prospects relative to the S&P 500.


**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue      |
|------------|---------|--------------|
| 2024-10-23 | $1.12   | $22.47B      |
| 2024-07-25 | $1.95   | $22.45B      |
| 2024-05-01 | $1.35   | $21.38B      |
| 2024-02-16 | $1.68   | $21.39B      |
| 2023-10-27 | $10.32  | $21.35B      |

There's a significant drop in EPS from October 2023 ($10.32) to the subsequent quarters. This needs further investigation to determine the cause (e.g., one-time events, seasonal factors, changing market conditions).  Revenue remains relatively stable.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue      | Profit Margin |
|---------|--------------|---------------|
| 2024-09-30 | $22.47B      | 69.01%        |
| 2024-06-30 | $22.45B      | 69.40%        |
| 2024-03-31 | $21.38B      | 69.55%        |
| 2023-12-31 | $21.39B      | 68.23%        |
| 2023-09-30 | $21.35B      | 69.06%        |

Revenue is relatively stable, with high and consistent profit margins.

**Capital and Profitability:**

| Quarter | Equity      | ROE    |
|---------|--------------|--------|
| 2024-09-30 | $70.16B      | 3.84%  |
| 2024-06-30 | $71.54B      | 6.55%  |
| 2024-03-31 | $70.02B      | 4.65%  |
| 2023-12-31 | $68.77B      | 5.89%  |
| 2023-09-30 | $71.23B      | 36.54% |

Equity is relatively stable.  The exceptionally high ROE in Q3 2023 requires further investigation to understand the contributing factors. The subsequent quarters show a considerably lower ROE.


**7. Overall Analysis:**

JNJ shows mixed signals.  While it boasts stable revenue and high profit margins, its significant underperformance relative to the S&P 500 (-90.9%), a projected negative long-term return against the S&P 500 (-381%), and fluctuating EPS raise serious concerns.  The high ROE in Q3 2023 needs further examination, as it is an outlier.  Further due diligence is crucial before making any investment decisions.  The erratic EPS figures require a thorough analysis to understand the underlying drivers.  The consistently negative alpha suggests that JNJ has not delivered alpha in the past.  This requires an in-depth investigation of the company's strategy, market position, and competitive landscape to assess future prospects.

**8. Disclaimer:** This report is for informational purposes only and should not be considered investment advice.  Conduct thorough research and consult a financial advisor before making any investment decisions.
